Case TARGIT

Next-generation allergy vaccine

The TARGIT project will develop a next-generation allergy vaccine to treat grass-pollen induced allergic rhinitis and asthma effectively and life-long. The vaccine is based on unique glycans, covalently linked to clinically relevant grass pollen derived peptides.

A Proof-of-Concept will be generated for the product, entering clinical testing with the large pharma partner Allergopharma directly after this project, as well as for the core technology providing direct spin-off towards other allergens.

The project was awarded a Eurostars grant.

Newsletter

A must-have if you’re interested in getting your business to the next level